Optisulin to Replace Lantus

By Donna Itzen, Pharmacist Diabetes QLD.

Sanofi has released a second brand formulation of insulin glargine 100 units/ml. The new preparation is called OPTISULIN® and is already listed on the Pharmaceutical Benefits Scheme (PBS) as of 1st January, 2020. It is currently listed alongside  LANTUS® which will be removed from the PBS as of the 1st July, 2020. Read more for what you need to know:

 

  • OPTISULIN® is a second brand of insuline glargine 100 units/ml and is ‘A’ flagged, which means pharmacies can substitute without prescriber endorsement.
  • The formulation, excipients and manufacturing process of OPTISULIN® is the same as LANTUS®.
  • People currently using LANTUS® may transition to OPTISULIN®. No dose adjustment is required when transitioning from LANTUS® to OPTISULIN® and patients should continue to titrate/adjust their dose as directed by their treating clinician.
  • OPTISULIN® is available in disposable pens (SoloStar®) and cartridges for reusable pens (AllStar Pro® and JuniorStar®). The cartridges will fit in existing Sanofi reusable pens.
  • As with LANTUS®, reusable pens from other companies are not correctly calibrated for OPTISULIN® dosing and should not be used.
  • Toujeo (insulin glarginr 300 units/ml) will continue as previously.
  • Through a partnership with the Australian Diabetes Educators Association (ADEA), Sanofi insulin patients can call 1900 2 746 753 and speak with a Credentialled Diabetes Educator (CDE). This includes a translator service and is free.
  • OPTSULIN® PBS code is 9039R.
    • Cartridges or disposable pens quantity 5 packs of 5 cart/pens with 1 repeat
    • Safety price $41.00 general and $6.60 concessional
    • Unrestricted

Do you want to learn more about Diabetes? Click here to find out more about Diabetes in Practice for Pharmacists course

Please wait...

Subscribe to our Monthly eNews

Receive the latest diabetes news, education, resources and special offers!